November 21, 2018 Regulatory LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
July 30, 2018 Regulatory New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology
June 7, 2018 Regulatory LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue
May 16, 2018 Regulatory LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company
May 15, 2018 Regulatory LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery
March 15, 2018 Regulatory LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field
February 8, 2018 Regulatory LIDDS: Liproca® Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine
January 10, 2018 Regulatory LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model